Ondine Biomedical Inc. Notice of AGM (2546Y)

TIDMOBI

RNS Number : 2546Y

Ondine Biomedical Inc.

03 May 2023

3 May 2023

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Notice of AGM

Ondine Biomedical Inc. (AIM: OBI) announces that the notice of the Company's 2023 Annual General Meeting ("AGM") and the associated form of proxy have been published today on the Company's website at https://ondinebio.com/investors/reports-documentation/ .

Printed copies of the notice of AGM and form of proxy will be posted today to registered shareholders who have elected to receive paper communications.

The Company's AGM will be held virtually at 8:00 a.m. (Pacific time) on 24 May 2023. Details of how to access the meeting are contained in the notice of AGM.

All shareholders are encouraged to submit their vote by proxy, well in advance of the meeting. Details of how to vote by proxy are contained in the notice of AGM. All valid proxy votes (whether submitted electronically or in hard copy form) will be included in the poll vote to be taken at the meeting.

The result of the AGM will be announced after its conclusion and published on the Company's website.

A separate release will be made relating to the announcement of Ondine's full year results to 31 December 2022 and the expected publication of the Company's Annual Report and Accounts.

**ENDS**

 
 Ondine Biomedical Inc. 
                                              +001 (604) 
 Angelika Vance, Corporate Communications      838 2702 
 
 Singer Capital Markets (Nominated Adviser 
  and Joint Broker) 
                                              [phone] 
 Aubrey Powell, Asha Chotai, Sam Butcher       3000 
 
 RBC Capital Markets (Joint Broker) 
                                              [phone] 
 Rupert Walford, Kathryn Deegan                4000 
 
 Vane Percy & Roberts (Media Contact) 
                                              [phone] 
 Simon Vane Percy, Amanda Bernard              5910 
 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered life sciences company that is the leader in photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include treatments for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.

About photodisinfection

Ondine's photodisinfection is a patented technology using a proprietary photosensitizer (non-antibiotic, light-activated solution) to destroy pathogens. When illuminated with a specific wavelength of light, the photosensitizer is activated, causing an oxidative burst that is lethal to all types of pathogens.

Ondine's nasal photodisinfection system has a CE mark and is approved in Canada and several other countries under the name Steriwave(TM). It has been used in Canada for over ten years, with no serious adverse events reported. In the US, it is currently undergoing clinical trials for regulatory approval.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAAJMRTMTMMMTJ

(END) Dow Jones Newswires

May 03, 2023 03:02 ET (07:02 GMT)